Evidence map›Paper›PMID 40138393›Full record

ArticleScience advances2025

An in vivo screen identifies NAT10 as a master regulator of brain metastasis.

Jocelyn F Chen, Peng Xu, Wesley L Cai, Huacui Chen, Emily Wingrove, Xiaojian Shi, Wenxue Li, Giulia Biancon, Meiling Zhang, Amer Balabaki and 12 more

Abstract read
In one paragraph

Article in Science advances, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 7 papers.

0numbers the graph read from it
0cells of the map it votes in
7citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

7 citing papers in PubMed.

  1. Review
  2. Review
  3. Article
  4. Article
  5. Review
  6. Article
  7. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

22 authors.

Jocelyn F ChenDepartment of Pathology, Yale School of Medicine, New Haven, CT 06520, USA.ORCID 0000-0001-7281-8686
Peng XuDepartment of Pathology, Yale School of Medicine, New Haven, CT 06520, USA.ORCID 0000-0003-0822-700X
Wesley L CaiDepartment of Pathology, Yale School of Medicine, New Haven, CT 06520, USA.ORCID 0000-0002-3871-5509
Huacui ChenDepartment of Pathology, Yale School of Medicine, New Haven, CT 06520, USA.ORCID 0000-0002-2768-4268
Emily WingroveDepartment of Pathology, Yale School of Medicine, New Haven, CT 06520, USA.
Xiaojian ShiDepartment of Cellular and Molecular Physiology, Yale School of Medicine, New Haven, CT 06510, USA.ORCID 0000-0001-7456-2901
Wenxue LiDepartment of Pharmacology, Yale Cancer Biology Institute, Yale University, West Haven, CT 06516, USA.ORCID 0000-0002-8902-0184
Giulia BianconYale Cancer Center, Yale School of Medicine, New Haven, CT 06520, USA.ORCID 0000-0003-0182-7766
Meiling ZhangDepartment of Pathology, Yale School of Medicine, New Haven, CT 06520, USA.ORCID 0009-0004-4859-2495
Amer BalabakiDepartment of Pathology, Yale School of Medicine, New Haven, CT 06520, USA.ORCID 0000-0002-1509-886X
Ethan D KropDepartment of Pathology, Yale School of Medicine, New Haven, CT 06520, USA.
Elianna AsareDepartment of Pathology, Yale School of Medicine, New Haven, CT 06520, USA.
Yangyi ZhangDepartment of Pathology, Yale School of Medicine, New Haven, CT 06520, USA.ORCID 0009-0000-4385-6472
Mingzhu YinDepartment of Pathology, Yale School of Medicine, New Haven, CT 06520, USA.ORCID 0000-0002-6964-7131
Toma TebaldiYale Cancer Center, Yale School of Medicine, New Haven, CT 06520, USA.ORCID 0000-0002-0625-1631
Jordan L MeierChemical Biology Laboratory, National Cancer Institute, National Institutes of Health, Frederick, MD 21702, USA.ORCID 0000-0002-0537-7101
Thomas F WestbrookTherapeutic Innovation Center (THINC), Verna & Marrs McLean Department of Biochemistry & Molecular Pharmacology, Department of Molecular and Human Genetics, and Dan L Duncan Comprehensive Cancer Center, Baylor College of Medicine, Houston, TX 77030, USA.
Stephanie HaleneDepartment of Pathology, Yale School of Medicine, New Haven, CT 06520, USA.ORCID 0000-0002-2737-9810
Yansheng LiuDepartment of Pharmacology, Yale Cancer Biology Institute, Yale University, West Haven, CT 06516, USA.ORCID 0000-0002-2626-3912
Hongying ShenDepartment of Cellular and Molecular Physiology, Yale School of Medicine, New Haven, CT 06510, USA.ORCID 0000-0002-2115-7037
Don X NguyenDepartment of Pathology, Yale School of Medicine, New Haven, CT 06520, USA.ORCID 0000-0003-0324-5604
Qin YanDepartment of Pathology, Yale School of Medicine, New Haven, CT 06520, USA.ORCID 0000-0003-4077-453X

Funding

A Novel Lineage Specific Metastasis Suppressor Pathway in Lung CancerR01CA166376 · NCI · YALE UNIVERSITY · PI NGUYEN, DON X · 2012 to 2024
$3.8M
Yale Cancer Biology Training GrantT32CA193200 · NCI · YALE UNIVERSITY · PI PETER M GLAZER, Qin Yan · 2016 to 2026
$3.6M
TARGETING HISTONE DEMETHYLASE KDM5B IN BREAST CANCERR01CA237586 · NCI · YALE UNIVERSITY · PI YAN, QIN · 2019 to 2023
$1.9M
NCI NIH HHS R01 CA166376NCI NIH HHS R01 CA237586NCI NIH HHS T32 CA193200
6 · The paper itself

Abstract

Emerging evidence has shown that epigenetic regulation plays a fundamental role in cancer metastasis, the major cause of cancer-related deaths. Here, we conducted an in vivo screen for vulnerabilities of brain metastasis and identified

Indexed as

Brain NeoplasmsBreast NeoplasmsN-Terminal Acetyltransferase EAnimalsCell Line, TumorCell MovementCell ProliferationFemaleGene Expression Regulation, NeoplasticHumansMiceNeoplasm MetastasisN-Terminal AcetyltransferasesPhosphoglycerate DehydrogenaseTransaminasesNAT10 protein, humanN-Terminal Acetyltransferase EN-Terminal AcetyltransferasesPhosphoglycerate Dehydrogenasephosphoserine aminotransferaseTransaminases

Identifiers

PMID40138393
PMCPMC11939035

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.